Ultimate men¡¯s prostate and urinary support
NET 1701
NET 1701Àº ¶ãº¸¸®¼ö ¹× ¹é¼ö¿À ÁÖÁ¤ÃßÃâ¹°À» À¯È¿¼ººÐÀ¸·Î ÇÏ´Â ³²¼º Àü¸³¼± °Ç°À» À§ÇÑ Æ¯Çã Á¶¼º¹°ÀÔ´Ï´Ù.
Àü¸³¼± ¼ºÀå¿¡ °ü¿©ÇÏ´Â Àü¸³¼± ƯÀÌÈ¿¼Ò 5¥á-reductase¸¦ ¾ïÁ¦ÇØ Àü¸³¼± ¼ºÀåÀ» ¿¹¹æ ¹× °³¼±Çϴµ¥ µµ¿òÀ» µå¸®¸ç
Å×½ºÅ佺Å×·Ð Áõ°¡·Î ¼º±â´É °ü·Ã ºÎÀÛ¿ë ¾øÀÌ ¾ÈÀüÇÏ°Ô ¼·ÃëÇÒ ¼ö ÀÖ½À´Ï´Ù.
Exclusivity
±¹°¡ | µî·Ï¹øÈ£ | ƯÇã ¸íĪ |
---|---|---|
´ëÇѹα¹ | 10-2195505 | ¶ãº¸¸®¼ö³ª¹« ¿¸Å ÃßÃâ¹°À» À¯È¿¼ººÐÀ¸·Î ÇÔÀ¯ÇÏ´Â Àü¸³¼±ºñ´ëÁõ ¿¹¹æ ¹× Ä¡·á¿ë Á¶¼º¹° (Pharmaceutical composition containing Elaeagnus multiflora Thunb. extract for treating and preventing benign prostatic hyperplasia) |
Mechanism of Action
5¥á-Reductase ¾ïÁ¦¸¦ ÅëÇÑ Àü¸³¼± ºñ´ë ¾ïÁ¦
Àü¸³¼±¾Ï LNCaP ¼¼Æ÷ÀÇ ´Ü¹éÁú ¹ßÇö È®ÀÎ
Àü¸³¼± ƯÀÌÈ¿¼Ò(5¥á-reductase), ¾Èµå·Î°Õ¼ö¿ëü(AR),
Àü¸³¼± ƯÀÌÇ׿ø(PSA) ´Ü¹éÁú ¹ßÇö ¾ïÁ¦
Àü¸³¼± ƯÀÌÇ׿ø(PSA) ´Ü¹éÁú ¹ßÇö ¾ïÁ¦
4ÁÖ°£ Åõ¿©, testosterone propionate Àü¸³¼± ºñ´ëÁõ À¯µµ
in vivo test °á°ú
in vivo test °á°ú
5¥á-reductase À¯ÀüÀÚ SRD5A2 ¹ßÇö ¾ïÁ¦
Àü¸³¼± ƯÀÌÇ׿ø PSA À¯ÀüÀÚ ¹ßÇö ¾ïÁ¦
Àü¸³¼± ¹«°Ô °¨¼Ò
Àü¸³¼± Áö¼ö °³¼±
TM3 Leydig cell °íȯ¼¼Æ÷
Å×½ºÅ佺Å×·Ð Áõ°¡
Clinical trial
ONGOING
to be completed in 2024
Recommended dosage
500 mg/day